|
1
|
Interleukin-2 and regulatory T cells in graft-versus-host disease.
|
N Engl J Med
|
2011
|
6.02
|
|
2
|
Rituximab for steroid-refractory chronic graft-versus-host disease.
|
Blood
|
2006
|
3.08
|
|
3
|
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.
|
Blood
|
2004
|
2.89
|
|
4
|
Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease.
|
Blood
|
2005
|
2.65
|
|
5
|
Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation.
|
Blood
|
2007
|
2.54
|
|
6
|
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.
|
Blood
|
2009
|
2.50
|
|
7
|
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.
|
J Clin Oncol
|
2008
|
2.44
|
|
8
|
Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation.
|
Blood
|
2011
|
2.41
|
|
9
|
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.
|
Blood
|
2004
|
2.30
|
|
10
|
Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.
|
Blood
|
2010
|
2.17
|
|
11
|
Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
2.11
|
|
12
|
Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.
|
Sci Transl Med
|
2013
|
2.03
|
|
13
|
Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.
|
J Clin Invest
|
2010
|
2.00
|
|
14
|
High levels of B-cell activating factor in patients with active chronic graft-versus-host disease.
|
Clin Cancer Res
|
2007
|
2.00
|
|
15
|
A disease risk index for patients undergoing allogeneic stem cell transplantation.
|
Blood
|
2012
|
2.00
|
|
16
|
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
|
Biol Blood Marrow Transplant
|
2006
|
1.99
|
|
17
|
Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group.
|
Cancer
|
2010
|
1.98
|
|
18
|
Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2004
|
1.91
|
|
19
|
Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis.
|
Blood
|
2010
|
1.88
|
|
20
|
Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study.
|
Biol Blood Marrow Transplant
|
2011
|
1.88
|
|
21
|
Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.
|
Biol Blood Marrow Transplant
|
2007
|
1.84
|
|
22
|
Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors.
|
Blood
|
2003
|
1.79
|
|
23
|
Prediction of veno-occlusive disease using biomarkers of endothelial injury.
|
Biol Blood Marrow Transplant
|
2010
|
1.76
|
|
24
|
Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL.
|
Blood
|
2013
|
1.74
|
|
25
|
Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation.
|
Blood
|
2003
|
1.73
|
|
26
|
Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation.
|
Blood
|
2013
|
1.72
|
|
27
|
Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.
|
Blood
|
2008
|
1.71
|
|
28
|
Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2005
|
1.70
|
|
29
|
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
|
Biol Blood Marrow Transplant
|
2008
|
1.69
|
|
30
|
Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.
|
J Clin Oncol
|
2012
|
1.68
|
|
31
|
Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion.
|
Blood
|
2013
|
1.67
|
|
32
|
The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.
|
Br J Haematol
|
2006
|
1.64
|
|
33
|
Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia: a report from the Eastern Cooperative Oncology Group.
|
J Clin Oncol
|
2004
|
1.61
|
|
34
|
Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
|
Biol Blood Marrow Transplant
|
2005
|
1.44
|
|
35
|
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age.
|
Biol Blood Marrow Transplant
|
2010
|
1.39
|
|
36
|
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
|
Biol Blood Marrow Transplant
|
2006
|
1.34
|
|
37
|
Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2008
|
1.27
|
|
38
|
Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
1.22
|
|
39
|
Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts.
|
Biol Blood Marrow Transplant
|
2011
|
1.19
|
|
40
|
Physicians' attitudes about quality-of-life issues in hematopoietic stem cell transplantation.
|
Blood
|
2004
|
1.19
|
|
41
|
Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.
|
J Infect Dis
|
2010
|
1.17
|
|
42
|
Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.
|
Blood
|
2013
|
1.14
|
|
43
|
Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
1.13
|
|
44
|
Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.
|
Blood
|
2009
|
1.12
|
|
45
|
Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
1.10
|
|
46
|
Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
|
Biol Blood Marrow Transplant
|
2013
|
1.08
|
|
47
|
Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2013
|
1.06
|
|
48
|
The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
1.06
|
|
49
|
A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2007
|
1.01
|
|
50
|
Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era.
|
Br J Haematol
|
2012
|
1.00
|
|
51
|
Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group.
|
Blood
|
2010
|
1.00
|
|
52
|
Does iron overload really matter in stem cell transplantation?
|
Am J Hematol
|
2012
|
0.99
|
|
53
|
Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.
|
J Infect Dis
|
2010
|
0.96
|
|
54
|
Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
0.94
|
|
55
|
Complementary medicine use among women enrolled in a genetic testing program.
|
Cancer Epidemiol Biomarkers Prev
|
2003
|
0.91
|
|
56
|
Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes.
|
Clin Cancer Res
|
2010
|
0.91
|
|
57
|
Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
|
Biol Blood Marrow Transplant
|
2009
|
0.90
|
|
58
|
Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
0.90
|
|
59
|
Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation.
|
Blood
|
2011
|
0.88
|
|
60
|
Validation of short-term handling and storage conditions for marrow and peripheral blood stem cell products.
|
Transfusion
|
2011
|
0.86
|
|
61
|
Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival.
|
Exp Hematol
|
2008
|
0.85
|
|
62
|
Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.
|
Cancer
|
2003
|
0.81
|
|
63
|
Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
|
Ann Hematol
|
2014
|
0.80
|
|
64
|
Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation.
|
Am J Hematol
|
2014
|
0.80
|
|
65
|
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.
|
Ann Hematol
|
2015
|
0.79
|
|
66
|
Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome.
|
Biol Blood Marrow Transplant
|
2010
|
0.79
|
|
67
|
Prognostic impact of KMT2E transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study.
|
Br J Haematol
|
2014
|
0.78
|
|
68
|
Engraftment syndrome after allogeneic hematopoietic cell transplantation in adults.
|
Am J Hematol
|
2014
|
0.77
|
|
69
|
Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17).
|
Med Oncol
|
2012
|
0.75
|
|
70
|
Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2013
|
0.75
|
|
71
|
The impact of medical education and networking on the outcome of leukemia treatment in developing countries. The experience of International Consortium on Acute Promyelocytic Leukemia (IC-APL).
|
Hematology
|
2012
|
0.75
|